GlassScriptPhysician profile
David Garcia
NPI 1902346570
$5,099.46
in general payments reported to CMS, 2019-2025
30 companies · $73.03 in 2025
The $73.03 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $149 · 2022: $1,758 · 2023: $2,890 · 2024: $229 · 2025: $73.03.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,133 · Gift: $59.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,133.28 |
| Gift | $59.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,017.70 | 2022-2023 | Farxiga |
| Novo Nordisk INC | $918.00 | 2021-2023 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $606.08 | 2022-2023 | Jardiance, Baqsimi, Lyumjev |
| Bayer Healthcare Pharmaceuticals INC. | $315.93 | 2022-2023 | |
| Radius Health, INC. | $315.69 | 2022-2024 | Tymlos |
| Sanofi-Aventis U.S. LLC | $279.11 | 2022-2025 | |
| Amgen INC. | $225.99 | 2022-2023 | Prolia, Evenity |
| Abbott Laboratories | $186.65 | 2022-2025 | Freestyle Libre 3 |
| Mannkind Corporation | $166.89 | 2022-2023 | Afrezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $148.14 | 2022-2023 | Jardiance |
| Alexion Pharmaceuticals, INC. | $128.70 | 2022-2024 | Ultomiris |
| Genentech USA, INC. | $99.94 | 2021 | |
| Abbvie INC. | $89.33 | 2022-2023 | |
| Intuity Medical INC | $75.68 | 2022-2023 | Pogo Automatic Blood Glucose Monitoring System |
| Antares Pharma, INC. | $66.74 | 2022-2023 | Nocdurna, Xyosted, Tlando |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $63.64 | 2022-2023 | Tepezza |
| Xeris Pharmaceuticals, INC. | $57.77 | 2022-2023 | Gvoke Hypopen |
| Tandem Diabetes Care, INC. | $55.28 | 2022-2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Novartis Pharmaceuticals Corporation | $52.42 | 2022-2023 | |
| Medtronic, INC. | $36.68 | 2023 | Intellis Adaptivestim |
| Beta Bionics, INC. | $30.26 | 2023 | Ilet Bionic Pancreas |
| Edwards Lifesciences Corporation | $23.62 | 2022 | |
| Cequr Corporation | $22.96 | 2023 | Cequr Simplicity |
| Exact Sciences Corporation | $20.98 | 2025 | Cologuard Collection Kit |
| Amphastar Pharmaceuticals, INC. | $19.64 | 2023 | Baqsimi |
| Amneal Pharmaceuticals LLC | $19.33 | 2023 | Unithroid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.02 | 2022 | |
| Tolmar, INC. | $15.03 | 2023 | |
| Ibsa Pharma INC. | $13.71 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $11.55 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Garcia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.